Skip to content
Precision for Medicine
Contact
iStock-1421515036 (2) iStock-1421515036 (2)

Profilage de l'expression génétique des biopsies

Le profilage de l'expression génétique des biopsies tumorales et des biopsies liquides peut fournir des informations sur l'inflammation et l'état immunitaire général.
Le profilage des biopsies par l'expression des gènes peut servir d'outil pour le dépistage des tumeurs susceptibles de répondre à des traitements tels que les inhibiteurs de points de contrôle, pour l'évaluation de l'efficacité thérapeutique, pour la mise en évidence du mécanisme d'action et pour toute une série d'autres applications.

Profilage complet et quantitatif de l'expression des gènes

Precision propose des tests de profilage de l'expression génique et de transcriptomique pour surveiller l'état immunitaire à l'aide des technologies de séquençage de nouvelle génération (NGS), NanoString, qPCR et Droplet Digital™ PCR (ddPCR). Pour les types d'échantillons et les besoins autres que le profilage immunitaire des biopsies, Precision propose également une suite complète d'applications génomiques.

Nos services sont conçus pour répondre aux objectifs de votre projet, que ce soit par le biais de panels préexistants ou d'un essai personnalisé.

Séquenceurs NGS Illumina et Thermo Fisher

Nous utilisons à la fois Illumina et Thermo Fisher pour le séquençage next-gen. Les études RNA-seq sont également réalisées avec Illumina, y compris le panel AmpliSeq for Illumina Immune Response Panel.

NanoString nCounter®

Pour les études quantitatives d'expression génique hautement multiplexées, nous utilisons la plateforme NanoString nCounter®. Ce système détecte directement l'ARN, évitant ainsi le risque de biais introduit par les approches basées sur l'amplification par PCR.

Nous pouvons utiliser les panels d'immuno-oncologie et d'immunologie de NanoString ou créer un panel personnalisé pour votre étude.

Système de PCR en temps réel QuantStudio™ 12K flex

Pour un profilage rentable et multiplexé de l'expression génique de nombreux échantillons en parallèle, nous proposons des analyses à l'aide de plaques OpenArray sur la plateforme qPCR QuantStudio 12K Flex.

QX200™ ddPCR™

La PCR numérique est appropriée lorsque des analyses très sensibles et une quantification absolue sont nécessaires. Precision utilise le système ddPCR QX200 de Bio-Rad.

Agena MassARRAY

Solution à haut débit pour le génotypage, la détection des mutations somatiques, l'analyse de la méthylation de l'ADN et l'analyse de la régulation de l'expression des gènes. Precision for Medicine propose les tests MassARRAY® soit en tant que service individuel, soit dans le cadre d'une offre globale de développement thérapeutique, qui comprend des tests de biomarqueurs et des essais cliniques.

Precision fournit également des échantillons biologiques prêts pour la recherche

En plus des services, Precision dispose d'échantillons biologiques prêts pour l'analyse génomique, ainsi que d'échantillons pré-caractérisés par NGS.

Tissus FFPE Explorer Biospécimens caractérisés par NGS Explorer Micropuces tissulaires Explorer

Explorer le blog de Precision

Lisez notre blog pour en savoir plus et découvrir les travaux soutenus par Precision.

Découvrez notre blog
Read: MHRA's International Recognition Procedure: Fast-Track Access to the UK Market MHRA's International Recognition Procedure: Fast-Track Access to the UK Market

Clinical Trials - Regulatory

MHRA's International Recognition Procedure: Fast-Track Access to the UK Market

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=195804116748, hs_child_table_id=0, hs_updated_at=1764696930757, hs_published_at=1764696947929, description=John is an experienced regulatory affairs consultant with more than 15 years of professional experience in drug development. He brings a proven track record in providing regulatory strategy, regulatory document development and review, and liaising with regulatory authorities., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/John%20McIntyre.png',altText='John McIntyre',fileId=201584594055}, lastname=McIntyre, PhD, hs_initial_published_at=1757516163742, hs_created_by_user_id=26433386, hs_created_at=1757515873736, hs_is_edited=false, hs_deleted_at=0, name=John, job=Senior Director, Regulatory Strategy, slug=john-mcintyre, hs_updated_by_user_id=51739740}, second={hs_id=200435431440, hs_child_table_id=0, hs_updated_at=1763745269993, hs_published_at=1764696947929, avatar=Image{width=636,height=476,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/AQ_GlobalAccess_AlexGrosvenor-3.jpg',altText='AQ_GlobalAccess_AlexGrosvenor-3',fileId=182031301743}, lastname=Grosvenor, hs_initial_published_at=1763745278294, hs_created_by_user_id=26433386, hs_created_at=1763745229272, hs_is_edited=false, hs_deleted_at=0, name=Alex, job=Alex Grosvenor is a Senior Vice President and Managing Director at Precision AQ. Based in London, Alex leads the International Pricing & Market Access Strategy team, which he established in September 2015. Over the past decade, he has built this team into a successful, thriving practice, with a reputation for delivering high-quality work and excellent recommendation for its clients. Alex brings more than 20 years’ consulting experience in the biopharmaceutical industry, over 15 of these in pricing & market access.He specialises in complex pricing strategies, including cross-indication strategy, launch-sequencing and international price referencing. He has worked across multiple therapy areas, including oncology, immunology, cardiovascular, orphan indications and cell & gene therapies., slug=alex-grosvenor, hs_updated_by_user_id=51739740}, third={}})
  • John M. avatar

    John M.
  • Alex G. avatar

    Alex G.
Découvrir
Read: New Zealand Clinical Trial Landscape: Speed, Quality & Savings Explained New Zealand Clinical Trial Landscape: Speed, Quality & Savings Explained

Clinical Trials

New Zealand Clinical Trial Landscape: Speed, Quality & Savings Explained

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=167906611101, hs_child_table_id=0, hs_updated_at=1762899997332, hs_published_at=1764696947929, description=Helen brings over 30 years of experience in multinational healthcare, biotech, and pharmaceutical industries, including work with Medical Research Institutes and CROs. She specializes in leading clinical research, drug and device development, and fostering innovative research collaborations. Based in Sydney, Australia, Helen has a strong track record of delivering clinical trials across the APAC region., avatar=Image{width=600,height=700,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Helene-Ormandy.png',altText='Helene-Ormandy',fileId=168387434767}, lastname=Ormandy, PhD, hs_initial_published_at=1716212950394, hs_created_by_user_id=2737751, hs_created_at=1716212897654, hs_is_edited=false, hs_deleted_at=0, name=Helen, job=Executive Director, Clinical Operations, slug=helen-ormandy, hs_updated_by_user_id=51739740}, second={hs_id=197935898186, hs_child_table_id=0, hs_updated_at=1761062728726, hs_published_at=1764696947929, description=Hardik Badani is a seasoned clinical research professional with a proven track record in managing complex, multi-regional clinical trials across North America, Europe, Asia-Pacific, and Africa. Based in Singapore, Hardik brings over a decade of experience in clinical operations, portfolio oversight, and project finance. He is a certified Project Management Professional (PMP) and was recognized with the Bronze award at the 2020 PharmaTimes International Clinical Researcher of the Year competition. Hardik’s expertise spans the full spectrum of clinical trial delivery—from startup through closeout—with a strong command of clinical systems including CTMS and EDC platforms. His leadership style emphasizes collaboration, operational excellence, and a deep commitment to advancing global health through precision-driven research., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Hardik%20Badani.png',altText='Hardik Badani',fileId=197937156662}, lastname=Badani, hs_initial_published_at=1761062733198, hs_created_by_user_id=26433386, hs_created_at=1761062663685, hs_is_edited=false, hs_deleted_at=0, name=Hardik, job=Principal Clinical Trial Manager, slug=hardik-badani, hs_updated_by_user_id=51739740}, third={}})
  • Helen O. avatar

    Helen O.
  • Hardik B. avatar

    Hardik B.
Découvrir
Read: Back to the Source: A Translational Leader on Extending the Living Legacy of Genomic Data Back to the Source: A Translational Leader on Extending the Living Legacy of Genomic Data

Translational Research - Biospecimens - Oncology

Back to the Source: A Translational Leader on Extending the Living Legacy of Genomic Data

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778886, hs_child_table_id=0, hs_updated_at=1763657611624, hs_published_at=1764696947929, description=Robert Snyder, PhD, is a seasoned expert with a 20-year track record in genomics, specializing in in vitro diagnostic assay development and bioinformatics. Committed to advancing medical science, he is proficient in regulatory V&V study designs and understands the nuances of orthogonal methods. A collaborative partner in biomedical development, Dr. Snyder champions the critical transition of biospecimens from benchtop to bedside., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Robert%20Snyder.webp',altText='Robert Snyder',fileId=165892444501}, linkedin=https://www.linkedin.com/in/robert-snyder-ph-d-9b67b035, hs_name=, hs_path=, lastname=Snyder, PhD, hs_initial_published_at=1764696935600, hs_created_at=1709645745117, hs_is_edited=false, hs_deleted_at=0, name=Robert, job=, slug=robert-snyder, email=, hs_updated_by_user_id=51739740}, second={hs_id=164691024166, hs_child_table_id=0, hs_updated_at=1716326265678, hs_published_at=1764696947929, description=Respected veteran of the biospecimen and biomarker laboratory services industry. Honed his expertise through leadership roles in organizations including Roche, Cancer Genetics, and BioServe. Holds a Master of Public Health and a Masters of Business Administration from the Johns Hopkins University., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Rob%20Fannon%20Headshot.webp',altText='Rob Fannon Headshot',fileId=165893006477}, linkedin=https://www.linkedin.com/in/rob-fannon-901378/, team=[{id=163072475009, name='Translational Sciences Leadership'}], lastname=Fannon, MPH, MBA, hs_initial_published_at=1713346931329, hs_created_by_user_id=62155952, hs_created_at=1713345787919, hs_is_edited=false, hs_deleted_at=0, name=Rob, job=General Manager, Biospecimen Solutions, slug=rob-fannon, hs_updated_by_user_id=51739740}, third={}})
  • Robert S. avatar

    Robert S.
  • Rob F. avatar

    Rob F.
Découvrir
Loading...